Other news to note for May 5, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Affibody, Alnylam, Anixa, Aravive, Astellas, Astrazeneca, Atreca, Bausch + Lomb, Beigene, Bioage Labs, Biocon, Bixink, Catalent, Celltrion, Clearside, Cytodyn, Daewoong, Edigene, Eli Lilly, Evergreenhealth, Fujifilm Diosynth, Generex, Gilead, Harbour, Heat Biologics, IGM Biosciences, Inovio, Insilico, J&J, Junshi, Lonza, Marinomed, Moderna, Mylan, Nanoviricides, Noachis Terra, Ology, Ontochem, Oragenics, Oxford Biodynamics, Pneumagen, Proteogenix, Puma, Recce, Sarepta, Secarna, Shionogi, Stabilitech, Taisho, Takis, Teva, Union, Vaxart, Verndari, Vir, Viralclear, Vistagen, Wuxi, Xbiotech USA, Xortx.

Earnings for May 5, 2020

Quarterly snapshots from biopharma companies with marketed products, including: Insmed.

Financings for May 5, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Pluristem.

Appointments and advancements for May 5, 2020

New hires and promotions in the biopharma industry in Asia-Pacific, including: Tessa Therapeutics.

Regulatory front for May 5, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Chugai, Pfizer, Roche, Therapeutic Goods Administration.

Clinical data for April 28-May 4, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aridis, Athersys, Biontech, Calcimedica, Chimerix, Cromos, Eiger, Eli Lilly, Geneone Life Science, Gilead Sciences, Gracell, I-Mab, Innate, Innovent, Inovio, Janssen, Lupin, Mesoblast, Morphosys, Novartis, Pfizer, R-Pharm, Synairgen, Yuhan.

Regulatory actions for April 28-May 4, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akarx, Algernon, Ascentage, Capricor, Combioxin, Cytodyn, Junshi, Moderna, Pharmamar, Remegen, Shionogi, Telix.

No Comments